BeOne Medicines Ltd. (ONC) operating KPIs
ONCNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as BEIGF
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 12/302313% above fair value
$370.33−1.23 (-0.33%)
Close on Oct 30, 2026Market cap $42.11BP/E 66.2Yield –
BeOne Medicines collaboration & Other Revenue — United States ($M) ($M)
Form 10-Q / 10-K Segment & Geographic Disaggregation Note
Latest, Q2 2026
15.6
Period ended Jun 30, 2026
Change on a year earlier
+73.3%
9 in Q2 2025
History
23 quarters
Since Q2 2020
Sources
16
Documents cited below
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Collaboration & Other Revenue — United States ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | 15.6 | +73.3% | Form 10-Q (filed 2026-08-05) ↗ |
| Q1 2026 | Mar 31, 2026 | 16.6 | +325.6% | Form 10-Q (filed 2026-05-06) ↗ |
| Q4 2025 | Dec 31, 2025 | 14 | +337.5% | Form 10-K (filed 2026-02-26) ↗ |
| Q3 2025 | Sep 30, 2025 | 12.2 | +617.6% | Form 10-Q (filed 2025-11-06) ↗ |
| Q2 2025 | Jun 30, 2025 | 9 | +328.6% | Form 10-Q (filed 2026-08-05) ↗ |
| Q1 2025 | Mar 31, 2025 | 3.90 | – | Form 10-Q (filed 2026-05-06) ↗ |
| Q4 2024 | Dec 31, 2024 | 3.20 | – | Form 10-K (filed 2026-02-26) ↗ |
| Q3 2024 | Sep 30, 2024 | 1.70 | -98.7% | Form 10-Q (filed 2025-11-06) ↗ |
| Q2 2024 | Jun 30, 2024 | 2.10 | -92.7% | Form 10-Q (filed 2025-08-06) ↗ |
| Q1 2024 | Mar 31, 2024 | 0 | -100.0% | Form 10-Q (filed 2025-05-07) ↗ |
| Q4 2023 | Dec 31, 2023 | 0 | -100.0% | Form 10-K (filed 2026-02-26) ↗ |
| Q3 2023 | Sep 30, 2023 | 128 | +406.7% | Form 10-Q (filed 2024-11-12) ↗ |
| Q2 2023 | Jun 30, 2023 | 28.8 | +11.2% | Form 10-Q (filed 2024-08-07) ↗ |
| Q1 2023 | Mar 31, 2023 | 25.7 | – | Form 10-Q (filed 2024-05-08) ↗ |
| Q4 2022 | Dec 31, 2022 | 30.1 | +150.8% | Form 10-K (filed 2025-02-27) ↗ |
| Q3 2022 | Sep 30, 2022 | 25.3 | +158.2% | Form 10-Q (filed 2023-11-09) ↗ |
| Q2 2022 | Jun 30, 2022 | 25.9 | +223.7% | Form 10-Q (filed 2023-08-02) ↗ |
| Q4 2021 | Dec 31, 2021 | 12 | – | Form 10-K (filed 2024-02-26) ↗ |
| Q3 2021 | Sep 30, 2021 | 9.80 | -70.9% | Form 10-Q (filed 2021-11-04) ↗ |
| Q2 2021 | Jun 30, 2021 | 8 | -49.7% | Form 10-Q (filed 2021-08-05) ↗ |
| Q1 2021 | Mar 31, 2021 | 350 | – | Form 10-Q (filed 2021-05-06) ↗ |
| Q3 2020 | Sep 30, 2020 | 33.7 | – | Form 10-Q (filed 2021-11-04) ↗ |
| Q2 2020 | Jun 30, 2020 | 15.9 | – | Form 10-Q (filed 2021-08-05) ↗ |
Cite this data
StockData. (2026). BeOne Medicines Collaboration & Other Revenue — United States ($M) ($M), quarterly Q2 2020–Q2 2026 [Data set]. Compiled from BeOne Medicines SEC filings and investor materials. https://stockdatahq.com/stocks/onc/kpis/rev_geo_collab_us
See every metric in the BeOne Medicines KPI table. Data updated Oct 29, 2026.